{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:17:40Z","timestamp":1777515460377,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The summary of product characteristics of vaccines administered intramuscularly, including the vaccine for coronavirus SARS-CoV-2 (COVID-19) and Influenza, warned for risks of bleeding in patients treated with oral anticoagulants. We aimed to estimate the incidence of major bleeding events in this setting and to compare these risks against other vaccination routes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This systematic review included all prospective and retrospective studies enrolling anticoagulated patients that received intramuscular vaccination, published until December 2020 in CENTRAL, MEDLINE and EMBASE. The outcomes of interest were major bleeding and haematoma related with vaccination. The incidence of the outcomes was estimated through a random-effects meta-analysis using the Freeman-Turkey transformation. The results are expressed in percentages, with 95%-confidence intervals (95%CI), limited between 0 and 100%. When studies compared intramuscular vaccination vs. other route, the data were compared and pooled using random-effects meta-analysis. Risk ratios (RR) with 95%CI were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall 16 studies with 642 patients were included. No major bleeding event was reported. The pooled incidence of haematomas following vaccination (mostly against Influenza) in patients treated with oral anticoagulants (mostly warfarin; no data with DOACs \/ NOACs) was 0.46% (95%CI 0-1.53%). Three studies evaluated the intramuscular vs. subcutaneous route of vaccination. Intramuscular vaccines did not increase the risk of haematoma (RR 0.53, 95%CI 0.10-2.82) compared with subcutaneous route.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Intramuscular vaccination in anticoagulated patients is safe with very low incidence of haematomas and the best available evidence suggests that using the intramuscular route does not increase the risk of haematomas compared with the subcutaneous route.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12959-022-00367-1","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T07:02:59Z","timestamp":1644994979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low risk of haematomas with intramuscular vaccines in anticoagulated patients: a systematic review with meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Daniel","family":"Caldeira","sequence":"first","affiliation":[]},{"given":"B\u00e1rbara Sucena","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"issue":"16","key":"367_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J, 39(16), 1330\u20131393 (2018).","journal-title":"Eur Heart J"},{"issue":"17","key":"367_CR2","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1136\/heartjnl-2016-310581","volume":"104","author":"A Tafur","year":"2018","unstructured":"Tafur A, Douketis J. Perioperative management of anticoagulant and antiplatelet therapy. Heart, 104(17), 1461\u20131467 (2018).","journal-title":"Heart"},{"key":"367_CR3","unstructured":"compendium) eem. Influvac Tetra - Summary of Product Characteristcs. (Ed.^(Eds) (2020)"},{"key":"367_CR4","unstructured":"Agency EM. Cominarty - Summary of Product Characteristics. (Ed.^(Eds) (2021)"},{"key":"367_CR5","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj, 339, b2700 (2009).","journal-title":"Bmj"},{"issue":"15","key":"367_CR6","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA, 283(15), 2008\u20132012 (2000).","journal-title":"JAMA"},{"issue":"9","key":"367_CR7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","volume":"65","author":"D Hoy","year":"2012","unstructured":"Hoy D, Brooks P, Woolf A et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol, 65(9), 934\u2013939 (2012).","journal-title":"J Clin Epidemiol"},{"key":"367_CR8","doi-asserted-by":"crossref","unstructured":"Nguyen KA, Peer N, Mills EJ, Kengne AP. A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population. PLoS One, 11(3), e0150970 (2016).","DOI":"10.1371\/journal.pone.0150970"},{"issue":"1","key":"367_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","volume":"72","author":"VN Nyaga","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health, 72(1), 39 (2014).","journal-title":"Arch Public Health"},{"issue":"11","key":"367_CR10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/jech-2013-203104","volume":"67","author":"JJ Barendregt","year":"2013","unstructured":"Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health, 67(11), 974\u2013978 (2013).","journal-title":"J Epidemiol Community Health"},{"issue":"1","key":"367_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/sim.2528","volume":"26","author":"MJ Bradburn","year":"2007","unstructured":"Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med, 26(1), 53\u201377 (2007).","journal-title":"Stat Med"},{"issue":"11","key":"367_CR12","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med, 21(11), 1539\u20131558 (2002).","journal-title":"Stat Med"},{"issue":"7109","key":"367_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj, 315(7109), 629\u2013634 (1997).","journal-title":"Bmj"},{"issue":"26","key":"367_CR14","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJM198306303082615","volume":"308","author":"PA Patriarca","year":"1983","unstructured":"Patriarca PA, Kendal AP, Stricof RL, Weber JA, Meissner MK, Dateno B. Influenza vaccination and warfarin or theophylline toxicity in nursing-home residents. N Engl J Med, 308(26), 1601\u20131602 (1983).","journal-title":"N Engl J Med"},{"issue":"6","key":"367_CR15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.7326\/0003-4819-100-6-835","volume":"100","author":"BA Lipsky","year":"1984","unstructured":"Lipsky BA, Pecoraro RE, Roben NJ, de Blaquiere P, Delaney CJ. Influenza vaccination and warfarin anticoagulation. Ann Intern Med, 100(6), 835\u2013837 (1984).","journal-title":"Ann Intern Med"},{"issue":"3","key":"367_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/clpt.1984.52","volume":"35","author":"P Kramer","year":"1984","unstructured":"Kramer P, Tsuru M, Cook CE, McClain CJ, Holtzman JL. Effect of influenza vaccine on warfarin anticoagulation. Clin Pharmacol Ther, 35(3), 416\u2013418 (1984).","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"367_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1532-5415.1985.tb07115.x","volume":"33","author":"IH Gomolin","year":"1985","unstructured":"Gomolin IH, Chapron DJ, Luhan PA. Lack of effect of influenza vaccine on theophylline levels and warfarin anticoagulation in the elderly. J Am Geriatr Soc, 33(4), 269\u2013272 (1985).","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"367_CR18","first-page":"499","volume":"5","author":"RT Weibert","year":"1986","unstructured":"Weibert RT, Lorentz SM, Norcross WA, Klauber MR, Jagger PI. Effect of influenza vaccine in patients receiving long-term warfarin therapy. Clin Pharm, 5(6), 499\u2013503 (1986).","journal-title":"Clin Pharm"},{"issue":"3","key":"367_CR19","first-page":"198","volume":"22","author":"HI Bussey","year":"1988","unstructured":"Bussey HI, Saklad JJ. Effect of influenza vaccine on chronic warfarin therapy. Drug Intell Clin Pharm, 22(3), 198\u2013201 (1988).","journal-title":"Drug Intell Clin Pharm"},{"issue":"4","key":"367_CR20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1742-1241.1990.tb10760.x","volume":"44","author":"WS Arnold","year":"1990","unstructured":"Arnold WS, Mehta MK, Roberts JS. Influenza vaccine and anticoagulation control in patients receiving warfarin. Br J Clin Pract, 44(4), 136\u2013139 (1990).","journal-title":"Br J Clin Pract"},{"issue":"14","key":"367_CR21","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/archinte.1995.00430140104011","volume":"155","author":"G Raj","year":"1995","unstructured":"Raj G, Kumar R, McKinney WP. Safety of intramuscular influenza immunization among patients receiving long-term warfarin anticoagulation therapy. Arch Intern Med, 155(14), 1529\u20131531 (1995).","journal-title":"Arch Intern Med"},{"issue":"3","key":"367_CR22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/j.1875-9114.1998.tb03127.x","volume":"18","author":"JC Delafuente","year":"1998","unstructured":"Delafuente JC, Davis JA, Meuleman JR, Jones RA. Influenza vaccination and warfarin anticoagulation: a comparison of subcutaneous and intramuscular routes of administration in elderly men. Pharmacotherapy, 18(3), 631\u2013636 (1998).","journal-title":"Pharmacotherapy"},{"issue":"5","key":"367_CR23","first-page":"599","volume":"88","author":"U Paliani","year":"2003","unstructured":"Paliani U, Filippucci E, Gresele P. Significant potentiation of anticoagulation by flu-vaccine during the season 2001-2002. Haematologica, 88(5), 599\u2013600 (2003).","journal-title":"Haematologica"},{"issue":"8","key":"367_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1157\/13072321","volume":"124","author":"M Ballester Torrens Mdel","year":"2005","unstructured":"Ballester Torrens Mdel M, Aball\u00ed Acosta M, Maudos P\u00e9rez MT et al. [Intramuscular route for the administration of the anti-flu vaccine in patients receiving oral anticoagulation therapy]. Med Clin (Barc), 124(8), 291\u2013294 (2005).","journal-title":"Med Clin (Barc)"},{"issue":"7","key":"367_CR25","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/pds.1347","volume":"16","author":"P MacCallum","year":"2007","unstructured":"MacCallum P, Madhani M, Mt-Isa S, Ashby D. Lack of effect of influenza immunisation on anticoagulant control in patients on long-term warfarin. Pharmacoepidemiol Drug Saf, 16(7), 786\u2013789 (2007).","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"367_CR26","first-page":"1","volume":"8","author":"J Casajuana","year":"2008","unstructured":"Casajuana J, Iglesias B, F\u00e0bregas M et al. Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-centre randomized controlled clinical trial. BMC Blood Disord, 8, 1 (2008).","journal-title":"BMC Blood Disord"},{"issue":"7","key":"367_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/archinternmed.2010.49","volume":"170","author":"A Iorio","year":"2010","unstructured":"Iorio A, Basileo M, Marcucci M et al. Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. Arch Intern Med, 170(7), 609\u2013616 (2010).","journal-title":"Arch Intern Med"},{"issue":"6","key":"367_CR28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.tmaid.2011.09.001","volume":"9","author":"R van Aalsburg","year":"2011","unstructured":"van Aalsburg R, van Genderen PJ. Vaccination in patients on anticoagulants. Travel Med Infect Dis, 9(6), 310\u2013311 (2011).","journal-title":"Travel Med Infect Dis"},{"issue":"8","key":"367_CR29","doi-asserted-by":"publisher","first-page":"e329-e332","DOI":"10.1097\/MPH.0000000000000662","volume":"38","author":"ME Bauman","year":"2016","unstructured":"Bauman ME, Hawkes M, Bruce A, Siddons S, Massicotte P. Immunizations in Children Requiring Warfarin Therapy. J Pediatr Hematol Oncol, 38(8), e329-e332 (2016).","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"367_CR30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1708-8305.2009.00304.x","volume":"16","author":"J Ringwald","year":"2009","unstructured":"Ringwald J, Strobel J, Eckstein R. Travel and oral anticoagulation. J Travel Med, 16(4), 276\u2013283 (2009).","journal-title":"J Travel Med"},{"issue":"10119","key":"367_CR31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S0140-6736(18)30143-0","volume":"391","author":"D Caldeira","year":"2018","unstructured":"Caldeira D, Ferreira JJ, Costa J. Influenza vaccination and prevention of cardiovascular disease mortality. Lancet, 391(10119), 426\u2013427 (2018).","journal-title":"Lancet"},{"issue":"1","key":"367_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ehjqcco\/qcaa030","volume":"7","author":"M Marques Antunes","year":"2021","unstructured":"Marques Antunes M, Duarte GS, Brito D et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes, 7(1), 97\u2013106 (2021).","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"5","key":"367_CR33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/heartjnl-2019-315193","volume":"106","author":"BS Rodrigues","year":"2020","unstructured":"Rodrigues BS, David C, Costa J, Ferreira JJ, Pinto FJ, Caldeira D. Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies. Heart, 106(5), 350\u2013357 (2020).","journal-title":"Heart"},{"key":"367_CR34","doi-asserted-by":"crossref","unstructured":"Rodrigues BS, Alves M, Duarte GS, Costa J, Pinto FJ, Caldeira D. The impact of influenza vaccination in patients with cardiovascular disease: An overview of systematic reviews. Trends Cardiovasc Med, (2020).","DOI":"10.1016\/j.tcm.2020.06.003"},{"key":"367_CR35","unstructured":"Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults \u2265 50 years with COVID-19. Journal of Arrhythmia, n\/a(n\/a))."},{"key":"367_CR36","unstructured":"England PH. COVID-19: The green book, chapter 14a. (Ed.^(Eds) (2020)"},{"issue":"11","key":"367_CR37","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.apmr.2018.04.023","volume":"99","author":"C Boulias","year":"2018","unstructured":"Boulias C, Ismail F, Phadke CP et al. A Delphi-Based Consensus Statement on the Management of Anticoagulated Patients With Botulinum Toxin for Limb Spasticity. Arch Phys Med Rehabil, 99(11), 2183\u20132189 (2018).","journal-title":"Arch Phys Med Rehabil"},{"issue":"1","key":"367_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11239-019-02013-6","volume":"50","author":"E Fox","year":"2020","unstructured":"Fox E, Misko J, Rawlins M, Manning L. The risk of intramuscular haematoma is low following injection of benzathine penicillin G in patients receiving concomitant anticoagulant therapy. J Thromb Thrombolysis, 50(1), 237\u2013238 (2020).","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"367_CR39","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/infdis\/125.6.656","volume":"125","author":"FL Ruben","year":"1972","unstructured":"Ruben FL, Jackson GG. A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis, 125(6), 656\u2013664 (1972).","journal-title":"J Infect Dis"},{"issue":"7-8","key":"367_CR40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.repc.2016.12.012","volume":"36","author":"D Caldeira","year":"2017","unstructured":"Caldeira D, Ferreira JJ, Pinto FJ. The era of the novel oral anticoagulants in Portugal. Rev Port Cardiol, 36(7-8), 577\u2013578 (2017).","journal-title":"Rev Port Cardiol"},{"issue":"9","key":"367_CR41","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/phar.2158","volume":"38","author":"J Zhu","year":"2018","unstructured":"Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017. Pharmacotherapy, 38(9), 907\u2013920 (2018).","journal-title":"Pharmacotherapy"},{"issue":"15","key":"367_CR42","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1136\/heartjnl-2015-307489","volume":"101","author":"D Caldeira","year":"2015","unstructured":"Caldeira D, Rodrigues FB, Barra M et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart, 101(15), 1204\u20131211 (2015).","journal-title":"Heart"},{"issue":"7","key":"367_CR43","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/pds.1386","volume":"16","author":"ML Jackson","year":"2007","unstructured":"Jackson ML, Nelson JC, Chen RT, Davis RL, Jackson LA. Vaccines and changes in coagulation parameters in adults on chronic warfarin therapy: a cohort study. Pharmacoepidemiol Drug Saf, 16(7), 790\u2013796 (2007).","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-022-00367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-022-00367-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-022-00367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T15:20:57Z","timestamp":1700234457000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-022-00367-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["367"],"URL":"https:\/\/doi.org\/10.1186\/s12959-022-00367-1","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to methodology of systematic review and meta-analysis, ethical approval and participants consent was not needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have seen and approved the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DC has participated in educational meetings and\/or attended a conferences or symposia (including travel, accommodation) with Daiichi Sankyo, Menarini, Merck Serono and Roche, in the last 3 years. MA reported participation in conferences with Boehringer-Ingelheim, AstraZeneca, Bayer, Bristol-Myers-Squibb, Gr\u00fcnenthal, Tecnimede, Merck Sharp & Dohme. FJP had consultant and speaker fees with Astra Zeneca, Bayer, BMS, Boehringer Ingelheim and Daiichi Sankyo. JJF is a consultant for Ipsen, GlaxoSmithKline, Novartis, Teva, Lundbeck, Solvay, Abbott, BIAL, Merck-Serono, and Merz; received grants from GlaxoSmithKline, Grunenthal, Teva, and Funda\u00e7\u00e3o MSD.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}